2022
DOI: 10.1016/j.biopha.2022.113519
|View full text |Cite
|
Sign up to set email alerts
|

SPARC in hematologic malignancies and novel technique for hematological disease with its abnormal expression

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

0
2
0

Year Published

2023
2023
2024
2024

Publication Types

Select...
4

Relationship

0
4

Authors

Journals

citations
Cited by 4 publications
(2 citation statements)
references
References 98 publications
0
2
0
Order By: Relevance
“…SPARC has been shown to be an important factor for drug accumulation [ 25 ]. Because SPARC has a high affinity with nanoparticle albumin-bound (NAB) molecule, lesions with high SPARC production show high response to drugs using NAB delivery technology [ 26 , 27 ]. In patients with head and neck cancer, NAB-paclitaxel drug remarkably reduced tumor size in SPARC-positive patients compared with that of the SPARC-negative group [ 27 ].…”
Section: Discussionmentioning
confidence: 99%
“…SPARC has been shown to be an important factor for drug accumulation [ 25 ]. Because SPARC has a high affinity with nanoparticle albumin-bound (NAB) molecule, lesions with high SPARC production show high response to drugs using NAB delivery technology [ 26 , 27 ]. In patients with head and neck cancer, NAB-paclitaxel drug remarkably reduced tumor size in SPARC-positive patients compared with that of the SPARC-negative group [ 27 ].…”
Section: Discussionmentioning
confidence: 99%
“…Other drug formulations that bind to albumin in vitro or in vivo are currently at different clinical stages. 22
Figure 1 Marketed albumin nanodrug products.
…”
Section: Introductionmentioning
confidence: 99%